Takeda Pharmaceutical (TAK) Stock Price & Analysis
Score
AI Analysis
SnapshotTakeda Pharmaceutical is a mixed profile at 53/100 — Value 53, Growth 60, Quality 47. Under the hood: P/E 28.5, about 20% below its own multi-year median, plus revenue compounding ~4% annually over recent years.
Price History
Price: —
Fair value: —
—
P/E (TTM): —
Net Income (TTM): —
Score: —
—
Score Breakdown
Market percentile scores loading…
Value
Growth
Quality
Financial Summary
Takeda Pharmaceutical Company Limited (TAK) last printed $21.41. Equity value is $69.55B. Trailing earnings multiple 28.48. The revenue row is reported history. Targets and ratings are on the forecast page.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| $1.73T | $1.77T | $2.1T | $3.29T | $3.2T | $3.57T | $4.03T | $4.26T | $4.58T | $4.51T |
About
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.